Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumretuzumab - Roche

Next Previous
Drug Profile

Lumretuzumab - Roche

Alternative Names: anti-HER3 monoclonal antibody - Roche; GE-HuMAb-HER3; HER3 MAb solid tumours - Roche; RG-7116; RO-5479599

Latest Information Update: 27 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 27 Sep 2021 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease) in France, Germany, Spain, Denmark (IV) (Roche pipeline, September 2021)
  • 27 Sep 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Spain, South Korea, Denmark, Netherlands (IV) (Roche pipeline, September 2021)
  • 27 Sep 2021 Discontinued - Phase-I for Solid tumours in Switzerland (IV) (Roche pipeline, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top